About this Research Topic
Also in the field of conventional therapy, many new data have confirmed the effectiveness of “old” drugs, such as hydroxychloroquine, methotrexate and azathioprine, demonstrating several additional beneficial properties for the treatment of Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) or other autoimmune diseases. Moreover, immunosuppressant developed to prevent graft rejection such as mycophenolate or tacrolimus have been demonstrated to have an important role in the treatment of rheumatic patients.
Beside the well defined anti-inflammatory properties of biological and synthetic anti-rheumatic drugs, a number of additional beneficial effects have been suggested, that have been hypothesized to prevent long term complications of autoimmune diseases, such as accelerated atherosclerosis, increased cardiovascular risk and osteoporosis.
The aim of this Research Topic is to collect new information regarding safety and effectiveness of new and old drugs for the treatment of RA, SLE, or other autoimmune diseases.
Keywords: autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus, disease modifing anti- rheumatic drugs, biological therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.